Collaboration with King’s College London on the Formulation Development of SDX-21

SynDermix AG is proud to announce its collaboration with King’s College London for the development of its Nitric Oxide technology.



SynDermix AG is proud to announce the initiation of its collaboration with King’s College London to develop the Company’s proprietary Nitric-Oxide releasing technology. The Company will be working with the research team of Dr. Stuart Jones at the Institute of Pharmaceutical Science at King’s College.

The objective of the collaboration is to develop the formulation of SDX-21, a technology based on a Nitric Oxide donor compound S-Nitrosoglutathione (GSNO), which facilitates the sustained release of Nitric Oxide. In parallel, the team will work on integrating the formulation with a specialised medical device.

Dr. Jones, who will be leading the team at King’s College London, commented: ‘In proof of concept studies, SDX-21 has shown extremely positive results. SDX-21 provides a truly innovative solution to the formulation and delivery of nitrous oxide.’ Mr. Dieter Hemmer, the CEO of SynDermix, stated: ‘SynDermix is thrilled to embark on this project with the Institute of Pharmaceutical Science at King’s. We expect that the formulation development of SDX-21 and its integration with an applicator device will prepare us to initiate studies in animal models by the end of this year.’


About King’s College London

King’s College London is one of the top 10 UK universities in the world (QS World University Rankings, 2020) and among the oldest in England. King’s has more than 31,000 students (of whom nearly 12,800 are graduate students) from some 150 countries worldwide, and some 8,500 staff. King’s has an outstanding reputation for world-class teaching and cutting-edge research. In the 2014 Research Excellence Framework (REF), eighty-four percent of research at King’s was deemed ‘world-leading’ or ‘internationally excellent’ (3* and 4*). Since our foundation, King’s students and staff have dedicated themselves in the service of society. King’s will continue to focus on world-leading education, research and service, and will have an increasingly proactive role to play in a more interconnected, complex world. Visit our website to find out more about Vision 2029, King’s strategic vision for the next 12 years to 2029, which will be the 200th anniversary of the founding of the university.


About SynDermix AG

SynDermix AG is a Swiss developer of innovative health technologies funded by private investors. The Company focuses on the development of effective and safe treatments that meaningfully respect patient convenience and address important unmet medical needs.

SynDermix has built a diversified portfolio of innovative assets which correspond to three distinct proprietary technology platforms: smart medical devices based on digital acoustic modulation; drugs and medical devices based on a topical nitric oxide-releasing formulation; and drug candidates based on a recombinant plant lectin. Its business model is to a large extent virtual, driven by a strategy of in-licensing, outsourcing and out-licensing; the Company enters into strategic partnerships with third parties for the acquisition, development and commercialisation of a robust portfolio of assets with high innovation value and commercial potential. For more information please visit:


SynDermix Management AG
Julian Heinrich

+41 44 366 40 16